Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl
Equity
Direct
Sector - Healthcare
NAV: ₹ 148.39 as on 18-04-2024
Fund Performance
74 people have invested ₹ 1.2L in Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl in the last three months
About the Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Sailesh Raj Bhan, Kinjal Desai. The fund could potentially beat inflation in the long-run.
Key Parameters
- Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl has ₹7125 Cr worth of assets under management (AUM) as on Mar 2024 and is more than category average.
- The fund has an expense ratio 0.9.
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl Overview
 | 0.92% |
 Benchmark | S&P BSE Healthcare PR |
 | ₹7125 Cr |
 | 1 January, 2013 |
 | ₹5000/₹100 |
 Exit Load | 1% |
 | No Lock-in |
 TurnOver | 18.67% |
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl Distribution as on (31-Mar-24)
Size breakup
Large cap
41.4%
Mid cap
33.1%
Small cap
22.6%
Sector Allocation
Health
100%
Top Holdings of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl as on (31-Mar-24)
Equity Holdings31
Debt Holdings1
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl: Monthly Changes Updates
All changes are between Jan'24 and Mar'24
Fund Performance
- This fund’s returns stands at -0.14% whereas the fund’s underlying benchmark Nifty 500 returns stands at -0.47% as on Mar'24
- This fund outperformed Nifty 500 by 0.33% in Mar'24
AUM Change
- AUM of the fund stands at 7.1K Cr as of Mar'24
- AUM decreased by 6.4 Cr between Mar'24 and Feb'24
Fund Portfolio Changes
Gainers & Losers in Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl portfolio Returns for the month of Mar
Top Growth Drivers | 1M Return |
|---|---|
 J B Chemicals & Pharmaceuticals Ltd | 16% |
Peer Analysis
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl Fund Manager
Sailesh Raj Bhan
Fund Manager of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl, since 1 April 2005
Top funds managed
Kinjal Desai
Fund Manager of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl, since 25 May 2018
Top funds managed
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 19.81% since inception which is less than its category average return of 20.36%
Fund Allocations
This fund has an allocation of 97.16% in Equity, 0% in Debt and 2.84% in Cash related instruments
AUM size ₹7125 Cr
This fund has AUM of ₹7125 Cr which is more than its category average of ₹ 1652 Cr
Expense Ratio 0.92%
This fund has an expense ratio of 0.92% which is less than its category average expense ratio of 1.45%
Frequently Asked Questions
The current NAV of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl is ₹148.39 as on 18-Apr-2024.
Existing (Absolute + CAGR) as on 18-Apr-2024.
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl | Absolute Returns | CAGR Returns |
1 Month Returns | 1.02% | 1.02% |
6 Month Returns | 21.43% | 21.43% |
1 Year Returns | 52.09% | 52.09% |
3 Years Returns | 66.96% | 18.63% |
5 Years Returns | 212.41% | 25.59% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.92% as on March 2024
₹7125 Cr as on March 2024
Sun Pharmaceuticals Industries Ltd(14.91%), Lupin Ltd(8.4%), Cipla Ltd(6.51%), Apollo Hospitals Enterprise Ltd(5.79%), Dr Reddy's Laboratories Ltd(4.75%) as on March 2024
The alpha ratio for the Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl | 1.2 | 3.41 | 5.93 |
As on March 2024
The alpha for Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl | 0.94 | 0.93 | 0.92 |
As on March 2024
The Beta for Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl | 2.91 | 1.04 | 1.08 |
As on March 2024
The sharpe ratio for Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl | 14.27 | 15.33 | 18.62 |
As on March 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.9 as on March 2024. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Information ratio is 0.98 as on March 2024. It tells the consistency of the fund in generating superior risk-adjusted performance
Sailesh Raj Bhan, Kinjal Desai are the fund managers of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl
The Exit load of Nippon India Pharma Fund Direct Plan Reinvestment Inc Dist cum Cap Wdrl is 1%